Overview

This trial is active, not recruiting.

Condition asthma
Treatments fluticasone 250 mg/salmeterol 50 mg, montelukast 10mg, theophylline 400 mg, ipratropium
Phase phase 4
Sponsor University of California, San Diego
Collaborator National Heart, Lung, and Blood Institute (NHLBI)
Start date October 2012
End date May 2015
Trial size 20 participants
Trial identifier NCT01696214, ARCTC-09, IR34HL109482-01A1

Summary

The primary aim of the pilot (SAPS) protocol is to determine the feasibility and utility of implementing the provisional design of the full scale TOM trial (e.g., the six month treatment period, the impact of the smoking cessation intervention).

There is no active hypothesis for the Vanguard Protocol.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model factorial assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Arm
(Placebo Comparator)
Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
ipratropium Atrovent
Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
(Placebo Comparator)
Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
theophylline 400 mg
Participants will be assigned to theophylline once a day for 24 weeks
(Placebo Comparator)
Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
montelukast 10mg Singulair
Participants will be assigned to montelukast once a day for 24 weeks.
(Placebo Comparator)
Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
fluticasone 250 mg/salmeterol 50 mg Advair(fluticasone/salmeterol)250/50
Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo

Primary Outcomes

Measure
Asthma Control Test
time frame: Outcome measures were determined at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and0 that a follow-up visit 1 month off study drug. Mean scores over the 24 weeks of treatment were compared.

Secondary Outcomes

Measure
The Asthma Symptom Utility Index(AUSI)
time frame: Outcome measures were determined at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and0 that a follow-up visit 1 month off study drug. Mean scores over the 24 weeks of treatmen
Physiologic Measures Were Determined at the Initial Visit, at Randomization Following a wash-in Period of 1 Month, Monthly for 24 Weeks and0 That a Follow-up Visit 1 Month Off Study Drug. Mean Scores Over the 24 Weeks of Treatment Were Compared.
time frame: At each visit

Eligibility Criteria

Male or female participants from 18 years up to 50 years old.

Inclusion Criteria: - Gender and Age: - Males and females, ages 18- 50 Current Smoker: - Smoke at least 5 cigarettes per day for at least 5 years - Positive urine cotinine test Asthma: - Physician diagnosed asthma - Symptomatic, as evidenced by - Use of SABA two or more times per week for relief of asthma symptoms, or - One or more nocturnal awakenings per week for asthma symptoms ACRC - SC MEETING - 19 MAY 2012 SAPS │ 25 Confidential, not for attribution or citation. - Pre-BD FEV1 greater than or equal to 40% predicted - Asthma diagnosis confirmed by either - albuterol reversibility of FEV1 by 12% or more, or - 20% fall in FEV1 at 8mg or less of methacholine - If over age 45, a DLco greater than 80% predicted - Females of childbearing potential: not pregnant, not lactating and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study. Exclusion Criteria: - Diagnosis of COPD or emphysema - Other major chronic illnesses in the opinion of the investigator that might interfere with the study: − e.g. including but not limited to uncontrolled diabetes, uncontrolled HIV infection or other immune system disorder, hyperthyroidism, seizure disorders, renal failure, liver disease, non-skin cancer, unstable psychiatric illness. - Recent active substance abuse (in past 6 months) - Lung disease other than asthma including COPD, bronchiectasis, sarcoidosis, or other significant lung disease - Unstable cardiac disease (decompensated CHF, unstable angina, recent MI, atrial fibrillation, supraventricular or ventricular tachycardia, congenital heart disease, or severe uncontrolled hypertension). - High risk of near fatal or fatal asthma as defined by the following 1-3 - ICU admission of asthma in the past year - more than 2 hospitalizations for asthma in the previous year - more than 3 ED visits for asthma in the previous year - intubation or ICU admission for asthma in the past 2 years - use of more than 2 canisters of inhaled short-acting beta2-agonist in past month - Acute asthma exacerbation in the past 4 weeks (treatment with systemic corticosteroids)

Additional Information

Official title SAPS:Smoking Asthmatics Pilot Study:
Principal investigator Joe Ramsdell, MD
Description The protocol is a small scale pilot of the full-scale TOM trial, and it will utilize a placebo design and incorporates 4 treatment arms. In the Vanguard Protocol all participants are to complete a 4 week run-in with Advair 100/50, followed by randomization to 1 of 4 arms of study treatment. The 4 drug treatment combinations are (2 inhalers, 2 pills): - Advair 250/50, Placebo, Placebo, Placebo - Advair 100/50 and montelukast, Placebo, Placebo - Advair 100/50 and theophylline, Placebo, Placebo - Advair 100/50 and ipratropium, Placebo, Placebo The 24 week treatment phase will be followed by a 4 week washout period on Advair 100/50. There is no crossover.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University of California, San Diego.